Alzheimer’s disease is a progressive brain disorder that slowly destroys memory, thinking skills, and eventually the ability to carry out basic daily tasks. It is the most common type of dementia, accounting for the majority of dementia cases worldwide. More than 55 million people globally live with some form of dementia, and that number is projected to reach 139 million by 2050.
An important distinction: dementia itself is not a disease. It’s an umbrella term for a decline in mental ability severe enough to interfere with daily life. Alzheimer’s is one specific cause of dementia, with its own distinct biology, progression pattern, and treatment options.
What Happens Inside the Brain
Two types of abnormal protein buildup drive Alzheimer’s. The first involves fragments of a protein called beta-amyloid, which clump together between nerve cells. The second involves a protein called tau, which twists into tangles inside neurons. Together, these changes disrupt the brain’s communication network and eventually kill brain cells.
The process starts years before any symptoms appear. Small, soluble clusters of beta-amyloid accumulate at the junctions where nerve cells communicate. These clusters are especially toxic early on, damaging synapses and interfering with how neurons send signals to each other. Interestingly, the larger visible plaques that form from amyloid may actually be less harmful on their own. Some researchers believe those plaques act as a kind of storage, trapping the smaller toxic clusters until they become overwhelmed.
Tau tangles develop later. Normally, tau helps maintain the internal scaffolding that neurons rely on to transport nutrients and signals. In Alzheimer’s, tau becomes chemically altered, detaches from that scaffolding, and clumps into tangles that choke the cell from the inside. The presence of amyloid appears to accelerate this process significantly. In animal studies, amyloid-rich brain tissue triggered far more tau tangle formation than tau-rich tissue alone, suggesting the two proteins feed off each other in a destructive cycle that spreads across the brain.
Early Warning Signs
Alzheimer’s often begins with mild cognitive impairment, a stage where memory and thinking changes are noticeable but don’t yet prevent someone from living independently. You might forget appointments more often, lose track of conversations, or struggle to estimate how long a task will take. Planning multi-step activities, like following a recipe or organizing a trip, becomes harder. Decision-making may feel slower or less reliable.
Not everyone with mild cognitive impairment progresses to Alzheimer’s. In the general population, roughly 4% of people with mild cognitive impairment convert to dementia each year. But that rate climbs significantly in people with certain risk factors, so catching changes early matters.
How Symptoms Progress Over Time
In the mild dementia stage, memory lapses become more disruptive. Getting lost in familiar places is common. Misplacing belongings, including valuable items, happens frequently. Personality shifts may emerge: someone who was easygoing might become withdrawn or irritable.
Moderate dementia brings deeper confusion. People lose track of the day, season, or where they are. Judgment deteriorates noticeably. Some people experience hallucinations, seeing or hearing things that aren’t there. Others develop paranoid beliefs, such as accusing a partner of infidelity. Restlessness and agitation tend to worsen in the evening, a pattern sometimes called sundowning. At this stage, help with daily activities like dressing, bathing, and managing medications becomes necessary.
In severe dementia, communication fades almost entirely. Physical abilities decline sharply. Muscles stiffen, reflexes stop responding normally, and the ability to sit upright without support can disappear. Eventually, a person loses the ability to swallow and control bladder and bowel functions. At this point, full-time care is required.
Risk Factors and Genetics
Age is the single biggest risk factor. Most people diagnosed with Alzheimer’s are 65 or older, and the risk roughly doubles every five years after that. But Alzheimer’s is not an inevitable part of aging.
Genetics play a role, particularly a gene variant called APOE-e4. Everyone inherits two copies of the APOE gene, one from each parent. Carrying one copy of the e4 variant increases Alzheimer’s risk and is linked to developing symptoms at a younger age. Carrying two copies raises the risk further. That said, some people with two copies never develop the disease, and many people who get Alzheimer’s carry no copies of e4 at all. Genetics load the odds but don’t determine the outcome.
Other risk factors include cardiovascular disease, diabetes, head injuries, hearing loss, social isolation, and depression. Many of these are modifiable, which means they can be addressed to potentially lower risk.
How Alzheimer’s Is Diagnosed
Diagnosis has shifted significantly in recent years. Updated criteria published in 2024 define Alzheimer’s as a biological disease, not just a collection of symptoms. This means doctors now rely heavily on biomarkers, measurable indicators of amyloid and tau in the brain or blood, rather than cognitive testing alone.
Blood tests that detect Alzheimer’s-related proteins are increasingly available, making early identification more practical than it was even a few years ago. Brain imaging and spinal fluid analysis remain options for confirming the diagnosis. Under current guidelines, biomarker testing is intended for people already showing symptoms, not for screening healthy individuals outside of research settings.
Treatment Options
For decades, Alzheimer’s medications could only manage symptoms without touching the underlying disease. That changed with a new class of treatments designed to clear amyloid from the brain. The FDA has approved infusion-based therapies that target amyloid plaques directly. One such treatment, donanemab, is given as an intravenous infusion every four weeks for up to 72 weeks. In clinical trials involving over 1,700 patients, these treatments slowed cognitive decline compared to placebo, though they did not stop it entirely.
These therapies work best when started early, before significant brain damage has occurred. They also carry risks, including brain swelling and small brain bleeds, which require regular monitoring through brain scans. Older medications that support the brain’s chemical messengers are still widely used to help with memory and thinking symptoms, particularly in moderate and severe stages.
Lifestyle Habits That Lower Risk
A study of nearly 3,000 adults found that people who consistently followed four or five healthy behaviors had substantially lower risk of developing Alzheimer’s. Those behaviors were: getting at least 150 minutes of physical activity per week, not smoking, limiting alcohol, eating a plant-based or high-quality diet, and keeping the mind active even later in life.
No single habit was a magic bullet. The protective effect came from the combination. Exercise appears to be particularly impactful, likely because it supports blood flow to the brain, reduces inflammation, and promotes the growth of new neural connections. Cognitive engagement, whether through learning new skills, reading, puzzles, or social interaction, helps build what researchers call cognitive reserve, essentially a buffer that allows the brain to tolerate more damage before symptoms appear.
Sleep quality also matters. During deep sleep, the brain clears waste products, including beta-amyloid. Chronic poor sleep has been linked to greater amyloid accumulation over time, creating a potential feedback loop where sleep disruption accelerates the very changes that later disrupt sleep further.